

AMT

AMT (Australian Medicines Terminology) has primarily been designed to enable interoperability between clinical solutions used within the healthcare sector. It provides a set of codes and descriptions to describe medicines for use across Australia. It is made up of information about the relationships between products, base and salt substance data, as well as information to enable the computation of product strengths.

MIMS has been providing a 'map' to AMT within the data provided to software partners for several months. Each month the editorial team updates this map with any additions or changes made to the AMT as well as changes within the MIMS content.

AMT provides a model for standard codes and descriptions for generics and brands. MIMS maps this code to the generics and brands currently marketed within Australia. By combining AMT mapping with the established MIMS data, which is widely deployed by clinical applications, we enable AMT to be rapidly incorporated by clinical systems.

Last year nehta released a 'beta' version on AMT Version 3. Following consultation and feedback from stakeholders, a preproduction version of AMT Version 3 has now been released. The availability of this preproduction version is to allow users of AMT to become familiar with the changes in structure compared to version 2. Further information on version 3 can be found at <https://www.nehta.gov.au/>

The current map delivered by MIMS will not be altered by the change from AMT V2 to V3. Any partners who are currently using the MIMS to AMT map will be able to support AMT version 3 in their applications without any change to their current use of our version 2 mapping.

